NW008 / Chipscreen - LARVOL DELTA

Preclinical study of NW008, a novel dual-functional anti-MICA/B antibody-drug conjugate (AACR 2026) - "MICA/B represents a highly attractive target for ADC development. NW008 is a first-in-class dual-functional ADC that acts by restoring antitumor immunity through inhibition of MICA/B shedding and directly eliminating tumor cells via targeted delivery of a topoisomerase I inhibitor. NW008 demonstrates robust antitumor efficacy in preclinical models, supporting its clinical development as a promising therapeutic candidate for MICA/B‑positive solid tumors."

ADC • Preclinical • Oncology • Solid Tumor • CD8 • MICA • MICB • NKG2D